INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY

Autor: JP Sharman, JM Melear, A Yacoub, SR Fanning, DJ Andorsky, GS Nowakowski, MJ Rummel, F Lansigan, J Li, JR Ahn, M Gharibo, M Coleman

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S73- (2021)

Objectives: The combination of lenalidomide + rituximab (R2) has shown complementary clinical activity and is a tolerable regimen in both untreated and relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL), as well as mantle cell lymphoma

Externí odkaz: https://doaj.org/article/035c7b2086924f859222e76f61ec7cac

PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA IN THE MAGNIFY PHASE 3B INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE

Autor: M Coleman, DJ Andorsky, A Yacoub, JM Melear, SR Fanning, KS Kolibaba, F Lansigan, C Reynolds, G Nowakowski, M Gharibo, E Ahn, J Li, MJ Rummel, JP Sharman

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S98- (2021)

Objectives: Relapse is expected when treating patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL), with a shortened response associated with each relapse. Lenalidomide combined with rituximab (R2) has shown enhanced activity, with

Externí odkaz: https://doaj.org/article/c4a2564782f24e20971aeb2d2c6d05d0

OUTREACH: Phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.

Autor: Linhares Y; Baptist Health, Miami Cancer Institute, Miami, Florida, United States., Freytes CO; Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, United States., Cherry M; Atlantic Health System, Carol Simon Cancer Center, Morristown, New Jersey, United States., Bachier C; Sarah Cannon Transplant & Cellular Therapy, San Antonio, Texas, San Antonio, Texas, United States., Maris MB; Colorado Blood Cancer Institute and Sarah Cannon Research Institute, United States., Hoda D; Intermountain Healthcare, Loveland Clinic for Blood Cancer Therapy, Salt Lake City, Utah, United States., Varela JC; Orlando Health Cancer Institute, Orlando, Florida, United States., Bellomo C; New York Oncology Hematology, Albany, New York, United States., Cross S; Virginia Oncology Associates, Norfolk, Virginia, United States., Essell JH; Oncology Hematology Care, United States., Fanning S; Prisma Health, Greenville, South Carolina, United States., Terebelo H; Providence Cancer institue, Southfield, Michigan, United States., Yimer HA; Texas Oncology, Tyler, Texas, United States., Courtright J; Texas Oncology-Medical City Dallas, Dallas, Texas, United States., Sharman JP; Willamette Valley Cancer Institute, United States., Kostic A; Bristol Myers Squibb, Seattle, Washington, United States., Vedal M; Bristol Myers Squibb, Seattle, Washington, United States., Ogasawara K; Bristol Myers Squibb, Princeton, New Jersey, United States., Avilion A; Bristol Myers Squibb, Seattle, Washington, United States., Espinola R; Bristol Myers Squibb, San Diego, California, United States., Yuan B; Bristol Myers Squibb, Princeton, New Jersey, United States., Mattar B; Cancer Center of Kansas, Wichita, Kansas, United States.

Publikováno v: Blood advances [Blood Adv] 2024 Sep 30. Date of Electronic Publication: 2024 Sep 30.

Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry.

Autor: Ghosh N; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Electronic address: nilanjan.ghosh@atriumhealth.org., Sharman JP; Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR, USA., Gutierrez M; Lymphoma Research Foundation, New York City, NY, USA., Khan W; Janssen, Horsham, PA, USA., Qureshi ZP; Janssen, Horsham, PA, USA., Raz A; AbbVie, North Chicago, IL, USA., Girardi V; AbbVie, North Chicago, IL, USA., Krigsfeld GS; AbbVie, North Chicago, IL, USA., Barrientos JC; Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Sep; Vol. 24 (9), pp. e301-e313. Date of Electronic Publication: 2024 May 13.

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials.

Autor: Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Sharman JP; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR., Ghia P; Division of Experimental Oncology, Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Eyre TA; Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Jurczak W; Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland., Siddiqi T; City of Hope Comprehensive Cancer Center, Duarte, CA., Miranda P; AstraZeneca, Gaithersburg, MD., Shahkarami M; AstraZeneca, South San Francisco, CA., Butturini A; AstraZeneca, South San Francisco, CA., Emeribe U; AstraZeneca, Gaithersburg, MD., Byrd JC; Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.

Publikováno v: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3345-3359.